Diabetic nephropathy market seen reaching $14.05 billion by 2035

Market Research Future forecasts the global diabetic nephropathy market will nearly double from $6.63 billion in 2026 to $14.05 billion by 2035, driven by rising diabetes rates, broader use of SGLT-2 and GLP-1 therapies, and reimbursement models tied to kidney function preservation. The shift toward earlier intervention is also reshaping diagnostics, care settings and regional demand. Why it matters: - Diabetic nephropathy is moving from a dialysis-heavy, late-stage treatment market to one centered on prevention and kidney function preservation. - The market’s projected growth reflects more diabetes cases worldwide and more patients being screened and treated earlier for kidney complications. - Payers and providers are increasingly rewarded for slowing disease progression, not just managing end-stage renal disease. What happened: - Market Research Future said the global diabetic nephropathy market will grow from $6.63 billion in 2026 to $14.05 billion by 2035, implying an 8.70% CAGR. - The market base was estimated at $6.10 billion in 2025. - The forecast was published June 19, 2026. - The report said rising diabetes prevalence, wider use of dual-mechanism therapies and value-based kidney care reimbursement are the main growth drivers. - The report also included a free sample request link: Request a free sample . The details: - The International Diabetes Federation projects the global adult diabetic population will rise from 589 million in 2024 to 853 million by 2050. - The report said about 30% to 40% of people with diabetes eventually develop progressive diabetic kidney damage. - Therapeutics held the largest product share in 2025 at about 72.1%. - Diagnostics is expected to be the fastest-growing product segment, at 8.85% CAGR from 2026 to 2035. - CKD stages 3 to 4 accounted for about 45.7% of revenue in 2025. - Hyperfiltration is projected to be the fastest-growing disease stage segment, at 10.20% CAGR. - Oral therapies held about 73.1% of route-of-administration revenue in 2025. - Injectable therapies are forecast to grow fastest, at 9.85% CAGR. - Hospitals represented about 44.9% of end-user revenue in 2025. - Specialty clinics are projected to grow fastest, at 8.60% CAGR. - The report listed detailed findings in the full report . - North America held about 43.0% of the market in 2025. - Europe was the second-largest regional market at $1.62 billion in 2025. - Asia-Pacific was the fastest-growing region, with a 9.20% CAGR from 2026 to 2035. - The Middle East and Africa region is projected to grow at 7.90% CAGR. - South America reached $0.38 billion in 2025. Between the lines: - The market is being pulled by a clear shift toward preventive kidney care, especially SGLT-2 inhibitors and GLP-1 receptor agonists. - CMS kidney care reimbursement models and similar value-based programs are making eGFR preservation a financial priority for providers. - The report said a single case progression to end-stage renal disease can cost payers about $60,000 to $100,000 over the care lifecycle in Europe. - That economic pressure is helping hospitals and clinics favor earlier intervention over reactive dialysis spending. - The competitive field is moderately concentrated, with the top five companies controlling an estimated 55% to 62% of global prescription revenue. - AstraZeneca, Novo Nordisk and Bayer are cited as major players in SGLT-2, GLP-1 and finerenone-based treatment segments. - The report said the FDA approved semaglutide for diabetic kidney damage indications in January 2025. - It also said Bayer presented pooled clinical data in June 2026 showing finerenone improved long-term cardiorenal protection. What’s next: - The report expects precision nephrology and biomarker-guided treatment to become more common by 2030. - It said about 40% of newly diagnosed diabetic nephropathy patients could receive biomarker-guided staging and matched SGLT-2/GLP-1 therapy by 2030. - The report said FDA and EMA acceptance of eGFR slope as a surrogate endpoint should shorten trial timelines and accelerate drug development. - Continued growth in AI-enabled monitoring and predictive screening could expand the diagnostics market alongside therapeutics. - More related research links were included in the source, including chronic kidney disease , diabetes devices , diabetes drugs , nephrostomy devices , renal dialysis , diabetes monitors and insulin delivery devices .